Developing a new targeted therapy for hormone-refractory prostate cancer: preclinical validation of everolimus-docetaxel containing nanoparticles.

Project Details

StatusFinished
Effective start/end date16/09/1615/04/17

Funding

  • Norfolk & Norwich University Hospitals NHS Foundation Trust: £26,341.62